

# Structural Basis of Zika Virus-Specific Antibody Protection

Cell

166, 1016-1027

DOI: [10.1016/j.cell.2016.07.020](https://doi.org/10.1016/j.cell.2016.07.020)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Recent Efforts in the Development of Therapies against Zika Virus. <i>Journal of Rare Disorders Diagnosis &amp; Therapy</i> , 2016, 02, .	0.1	0
2	Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. <i>Science Translational Medicine</i> , 2016, 8, 369ra179.	5.8	194
3	Zika Virus: Immunity and Vaccine Development. <i>Cell</i> , 2016, 167, 625-631.	13.5	113
4	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016, 354, 237-240.	6.0	348
5	Zika virus: from pathogenesis to disease control. <i>FEMS Microbiology Letters</i> , 2016, 363, fnw202.	0.7	62
6	Diagnostics for Zika virus on the horizon. <i>Science</i> , 2016, 353, 750-751.	6.0	27
7	Zika vaccine candidates progress through nonclinical development and enter clinical trials. <i>Npj Vaccines</i> , 2016, 1, 16023.	2.9	13
8	Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. <i>Nature</i> , 2016, 540, 443-447.	13.7	349
9	Fighting Infection in a Globalized World. <i>Cell</i> , 2016, 167, 583-585.	13.5	1
10	Human Vaccines & Immunotherapeutics: News. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2216-2218.	1.4	0
11	Zika virus infection damages the testes in mice. <i>Nature</i> , 2016, 540, 438-442.	13.7	430
12	A Multiplex Microsphere Immunoassay for Zika Virus Diagnosis. <i>EBioMedicine</i> , 2017, 16, 136-140.	2.7	83
13	Role of N-glycosylation on Zika virus E protein secretion, viral assembly and infectivity. <i>Biochemical and Biophysical Research Communications</i> , 2017, 492, 579-586.	1.0	59
14	Animal Models of Zika Virus Infection, Pathogenesis, and Immunity. <i>Journal of Virology</i> , 2017, 91, .	1.5	225
15	Preventive and therapeutic challenges in combating Zika virus infection: are we getting any closer?. <i>Journal of NeuroVirology</i> , 2017, 23, 347-357.	1.0	12
16	Future developments in biosensors for field-ready Zika virus diagnostics. <i>Journal of Biological Engineering</i> , 2017, 11, 7.	2.0	44
17	Prospects for a Zika Virus Vaccine. <i>Immunity</i> , 2017, 46, 176-182.	6.6	79
18	Modified mRNA Vaccines Protect against Zika Virus Infection. <i>Cell</i> , 2017, 168, 1114-1125.e10.	13.5	633

#	ARTICLE	IF	CITATIONS
19	Bridging Knowledge Gaps to Understand How Zika Virus Exposure and Infection Affect Child Development. <i>JAMA Pediatrics</i> , 2017, 171, 478.	3.3	64
20	Zika Virus Pathogenesis and Tissue Tropism. <i>Cell Host and Microbe</i> , 2017, 21, 134-142.	5.1	337
21	The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis. <i>Microbiology and Molecular Biology Reviews</i> , 2017, 81, .	2.9	156
22	Maternal-Fetal Transmission of Zika Virus: Routes and Signals for Infection. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 287-294.	0.5	44
23	Vaccination strategies against Zika virus. <i>Current Opinion in Virology</i> , 2017, 23, 59-67.	2.6	62
24	Temperature-dependent folding allows stable dimerization of secretory and virus-associated E proteins of Dengue and Zika viruses in mammalian cells. <i>Scientific Reports</i> , 2017, 7, 966.	1.6	36
25	Advances in research on Zika virus. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 321-331.	0.4	30
26	Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-6.	3.0	93
27	Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies. <i>Virology</i> , 2017, 508, 1-6.	1.1	20
28	Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion. <i>Journal of Virology</i> , 2017, 91, .	1.5	30
29	Potential mechanisms of Zika-linked microcephaly. <i>Wiley Interdisciplinary Reviews: Developmental Biology</i> , 2017, 6, e273.	5.9	38
30	Structural Biology of the Zika Virus. <i>Trends in Biochemical Sciences</i> , 2017, 42, 443-456.	3.7	98
31	A human antibody against Zika virus crosslinks the E protein to prevent infection. <i>Nature Communications</i> , 2017, 8, 14722.	5.8	122
32	Transfer of convalescent serum to pregnant mice prevents Zika virus infection and microcephaly in offspring. <i>Cell Research</i> , 2017, 27, 158-160.	5.7	39
33	Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	89
34	Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. <i>Nature Immunology</i> , 2017, 18, 1261-1269.	7.0	95
35	A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. <i>Cell</i> , 2017, 171, 229-241.e15.	13.5	118
36	Metastability Gap in the Phase Diagram of Monoclonal IgG Antibody. <i>Biophysical Journal</i> , 2017, 113, 1750-1756.	0.2	9

#	ARTICLE	IF	CITATIONS
37	Zika, Guillain-Barré y anestesiología: un punto de intersección entre la salud pública y la práctica clínica. Colombian Journal of Anesthesiology, 2017, 45, 269-271.	0.5	0
38	Zika virus has oncolytic activity against glioblastoma stem cells. Journal of Experimental Medicine, 2017, 214, 2843-2857.	4.2	179
39	Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Scientific Reports, 2017, 7, 7679.	1.6	100
40	Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. Cell, 2017, 170, 273-283.e12.	13.5	224
41	Monoclonal Antibodies against Zika Virus: Therapeutics and Their Implications for Vaccine Design. Journal of Virology, 2017, 91, .	1.5	36
42	Zika virus and diagnostics. Current Opinion in Pediatrics, 2017, 29, 107-113.	1.0	7
43	Current status of therapeutic and vaccine approaches against Zika virus. European Journal of Internal Medicine, 2017, 44, 12-18.	1.0	39
44	Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. Science Immunology, 2017, 2, .	5.6	98
45	Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus. Journal of Virology, 2017, 91, .	1.5	77
46	Zika, Guillain-Barré and anesthesiology: A point of intersection between public health and clinical practice. Colombian Journal of Anesthesiology, 2017, 45, 269-271.	0.5	0
47	Zika Virus Infects Intermediate Progenitor Cells and Post-mitotic Committed Neurons in Human Fetal Brain Tissues. Scientific Reports, 2017, 7, 14883.	1.6	42
48	Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine, 2017, 35, 4287-4294.	1.7	88
49	The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Research, 2017, 137, 134-140.	1.9	217
50	Zika and pregnancy: A comprehensive review. American Journal of Reproductive Immunology, 2017, 77, e12607.	1.2	12
51	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerging Microbes and Infections, 2017, 6, 1-11.	3.0	41
52	Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity. Journal of Infectious Diseases, 2017, 216, S906-S911.	1.9	34
53	Zika Virus Vaccine Development. Journal of Infectious Diseases, 2017, 216, S957-S963.	1.9	38
54	Zika, Guillain-Barré and anesthesiology: A point of intersection between public health and clinical practice†: Zika, Guillain-Barré y anestesiología: un punto de intersección entre la salud pública y la práctica clínica. Colombian Journal of Anesthesiology, 2017, 45, 269-271.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Understanding the Pathogenesis of Zika Virus Infection Using Animal Models. <i>Immune Network</i> , 2017, 17, 287.	1.6	19
56	Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. <i>Emerging Infectious Diseases</i> , 2017, 23, 773-781.	2.0	141
57	Zika Virus: What Have We Learnt Since the Start of the Recent Epidemic?. <i>Frontiers in Microbiology</i> , 2017, 8, 1554.	1.5	44
58	DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection. <i>PLoS ONE</i> , 2017, 12, e0181734.	1.1	34
59	Ontogeny of the B- and T-cell response in a primary Zika virus infection of a dengue-naïve individual during the 2016 outbreak in Miami, FL. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006000.	1.3	48
60	A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. <i>PLoS Pathogens</i> , 2017, 13, e1006178.	2.1	69
61	Immune Human Antibody Libraries for Infectious Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1053, 61-78.	0.8	4
62	Prolonged Detection of Zika Virus in Vaginal Secretions and Whole Blood. <i>Emerging Infectious Diseases</i> , 2017, 23, 99-101.	2.0	184
63	Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. <i>JCI Insight</i> , 2017, 2, .	2.3	74
64	Human IFIT3 Modulates IFIT1 RNA Binding Specificity and Protein Stability. <i>Immunity</i> , 2018, 48, 487-499.e5.	6.6	94
65	Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus. <i>MBio</i> , 2018, 9, .	1.8	32
66	A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity. <i>Vaccine</i> , 2018, 36, 1846-1852.	1.7	43
67	Insect cell-produced recombinant protein subunit vaccines protect against Zika virus infection. <i>Antiviral Research</i> , 2018, 154, 97-103.	1.9	28
68	Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models. <i>Journal of Drug Targeting</i> , 2018, 26, 905-912.	2.1	11
69	Development of vaccines against Zika virus. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e211-e219.	4.6	125
70	Congenital Zika virus infection as a silent pathology with loss of neurogenic output in the fetal brain. <i>Nature Medicine</i> , 2018, 24, 368-374.	15.2	117
71	Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies. <i>Nature Microbiology</i> , 2018, 3, 287-294.	5.9	42
72	Structure of tick-borne encephalitis virus and its neutralization by a monoclonal antibody. <i>Nature Communications</i> , 2018, 9, 436.	5.8	119

#	ARTICLE	IF	CITATIONS
73	Zika virus-related neurotropic flaviviruses infect human placental explants and cause fetal demise in mice. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	85
74	Cellular and Humoral Immunity Protect against Vaginal Zika Virus Infection in Mice. <i>Journal of Virology</i> , 2018, 92, .	1.5	54
75	Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-8.	3.0	41
76	Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	53
77	Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge. <i>EBioMedicine</i> , 2018, 27, 61-70.	2.7	46
78	The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. <i>EMBO Reports</i> , 2018, 19, 206-224.	2.0	188
79	Using immunocompromised mice to identify mechanisms of Zika virus transmission and pathogenesis. <i>Immunology</i> , 2018, 153, 443-454.	2.0	13
80	Structural biology of Zika virus and other flaviviruses. <i>Nature Structural and Molecular Biology</i> , 2018, 25, 13-20.	3.6	144
81	The Zika virus envelope protein glycan loop regulates virion antigenicity. <i>Virology</i> , 2018, 515, 191-202.	1.1	49
82	Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage. <i>Journal of Virology</i> , 2018, 92, .	1.5	72
83	A Single Injection of Human Neutralizing Antibody Protects against Zika Virus Infection and Microcephaly in Developing Mouse Embryos. <i>Cell Reports</i> , 2018, 23, 1424-1434.	2.9	29
84	Zika and the Eye: Pieces of a Puzzle. <i>Progress in Retinal and Eye Research</i> , 2018, 66, 85-106.	7.3	32
85	Infection by Zika viruses requires the transmembrane protein AXL, endocytosis and low pH. <i>Virology</i> , 2018, 518, 301-312.	1.1	67
86	Zika virus: from an obscurity to a priority. <i>Microbes and Infection</i> , 2018, 20, 635-645.	1.0	25
87	Evaluation of Possible Consequences of Zika Virus Infection in the Developing Nervous System. <i>Molecular Neurobiology</i> , 2018, 55, 1620-1629.	1.9	5
88	Plant-produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice. <i>Plant Biotechnology Journal</i> , 2018, 16, 572-580.	4.1	62
89	Beyond binding: antibody effector functions in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 46-61.	10.6	516
90	Zika virus structural biology and progress in vaccine development. <i>Biotechnology Advances</i> , 2018, 36, 47-53.	6.0	75

#	ARTICLE	IF	CITATIONS
91	Challenges of Vaccine Development for Zika Virus. <i>Viral Immunology</i> , 2018, 31, 117-123.	0.6	6
92	Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. <i>Nature Immunology</i> , 2018, 19, 20-28.	7.0	110
93	A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice. <i>Scientific Reports</i> , 2018, 8, 17385.	1.6	43
94	Ribosome display for the rapid generation of high-affinity Zika-neutralizing single-chain antibodies. <i>PLoS ONE</i> , 2018, 13, e0205743.	1.1	13
95	Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies. <i>MSphere</i> , 2018, 3, .	1.3	45
96	An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections. <i>Cell Reports</i> , 2018, 25, 3382-3392.e3.	2.9	79
97	An Evolutionary Insight into Zika Virus Strains Isolated in the Latin American Region. <i>Viruses</i> , 2018, 10, 698.	1.5	9
98	OptMAVEEn-2.0: De novo Design of Variable Antibody Regions Against Targeted Antigen Epitopes. <i>Antibodies</i> , 2018, 7, 23.	1.2	42
99	Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. <i>Nature Communications</i> , 2018, 9, 4560.	5.8	88
100	Research Models and Tools for the Identification of Antivirals and Therapeutics against Zika Virus Infection. <i>Viruses</i> , 2018, 10, 593.	1.5	16
101	Animal Models for Chikungunya Virus and Zika Virus. , 2018, , 317-346.		1
102	Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. <i>Nature Immunology</i> , 2018, 19, 1248-1256.	7.0	31
103	The immune response against flaviviruses. <i>Nature Immunology</i> , 2018, 19, 1189-1198.	7.0	126
104	Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. <i>Oncotarget</i> , 2018, 9, 5197-5207.	0.8	23
105	Host genetic control of mosquito-borne Flavivirus infections. <i>Mammalian Genome</i> , 2018, 29, 384-407.	1.0	13
106	The emergence of Zika virus and its new clinical syndromes. <i>Nature</i> , 2018, 560, 573-581.	13.7	303
107	Neutralizing antibodies against porcine epidemic diarrhea virus block virus attachment and internalization. <i>Virology Journal</i> , 2018, 15, 133.	1.4	18
108	Structures of Zika Virus E & NS1: Relations with Virus Infection and Host Immune Responses. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1062, 77-87.	0.8	13

#	ARTICLE	IF	CITATIONS
109	Zika virus infection in immunocompetent pregnant mice causes fetal damage and placental pathology in the absence of fetal infection. <i>PLoS Pathogens</i> , 2018, 14, e1006994.	2.1	83
110	Therapeutic Antibody Discovery in Infectious Diseases Using Single-Cell Analysis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1068, 89-102.	0.8	9
112	Expression of a Zika virus antigen in microalgae: Towards mucosal vaccine development. <i>Journal of Biotechnology</i> , 2018, 282, 86-91.	1.9	36
113	Development of Antibody Therapeutics against Flaviviruses. <i>International Journal of Molecular Sciences</i> , 2018, 19, 54.	1.8	51
114	A VSV-based Zika virus vaccine protects mice from lethal challenge. <i>Scientific Reports</i> , 2018, 8, 11043.	1.6	63
115	Disruption of glial cell development by Zika virus contributes to severe microcephalic newborn mice. <i>Cell Discovery</i> , 2018, 4, 43.	3.1	47
116	Prevention and Control Strategies to Counter Zika Virus, a Special Focus on Intervention Approaches against Vector Mosquitoesâ€”Current Updates. <i>Frontiers in Microbiology</i> , 2018, 9, 87.	1.5	39
117	Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice. <i>Journal of Virology</i> , 2018, 92, .	1.5	42
118	Potential targets for therapeutic intervention and structure based vaccine design against Zika virus. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 444-460.	2.6	16
119	Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. <i>Frontiers in Immunology</i> , 2018, 9, 597.	2.2	97
120	Zika virus vaccines: immune response, current status, and future challenges. <i>Current Opinion in Immunology</i> , 2018, 53, 130-136.	2.4	45
121	An Immunocompetent Mouse Model of Zika Virus Infection. <i>Cell Host and Microbe</i> , 2018, 23, 672-685.e6.	5.1	192
122	Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope. <i>Cell Host and Microbe</i> , 2018, 23, 618-627.e6.	5.1	28
123	Congenital Zika Virus Infection in Immunocompetent Mice Causes Postnatal Growth Impediment and Neurobehavioral Deficits. <i>Frontiers in Microbiology</i> , 2018, 9, 2028.	1.5	30
124	E90 subunit vaccine protects mice from Zika virus infection and microcephaly. <i>Acta Neuropathologica Communications</i> , 2018, 6, 77.	2.4	17
125	Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. <i>PLoS ONE</i> , 2018, 13, e0202820.	1.1	45
126	Novel neutralizing monoclonal antibodies against Junin virus. <i>Antiviral Research</i> , 2018, 156, 21-28.	1.9	15
127	Zika Virus Envelope Protein and Antibody Complexes. <i>Sub-Cellular Biochemistry</i> , 2018, 88, 147-168.	1.0	10



#	ARTICLE	IF	CITATIONS
128	Multivalent Interactions between 2D Nanomaterials and Biointerfaces. <i>Advanced Materials</i> , 2018, 30, e1706709.	11.1	112
129	Different footprints of the Zika and dengue surface proteins on viral membranes. <i>Soft Matter</i> , 2018, 14, 5615-5621.	1.2	10
130	Production of complex viral glycoproteins in plants as vaccine immunogens. <i>Plant Biotechnology Journal</i> , 2018, 16, 1531-1545.	4.1	65
131	Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models. <i>Journal of Virology</i> , 2018, 92, .	1.5	59
132	Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice. <i>PLoS ONE</i> , 2018, 13, e0194860.	1.1	41
133	Zika Virus. , 2018, , 1266-1267.e1.		0
134	Advances in the research and development of therapeutic antibodies against the Zika virus. <i>Cellular and Molecular Immunology</i> , 2019, 16, 96-97.	4.8	10
135	Yeast-produced subunit protein vaccine elicits broadly neutralizing antibodies that protect mice against Zika virus lethal infection. <i>Antiviral Research</i> , 2019, 170, 104578.	1.9	15
136	Peptide-Based Subunit Vaccine Design of T- and B-Cells Multi-Epitopes against Zika Virus Using Immunoinformatics Approaches. <i>Microorganisms</i> , 2019, 7, 226.	1.6	25
137	ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization. <i>Viruses</i> , 2019, 11, 748.	1.5	8
138	Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. <i>Vaccines</i> , 2019, 7, 72.	2.1	33
139	Immunological Assays used to Support Efficacy of Zika Virus Vaccines. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 97.	0.9	3
140	Zika Virus NS3 Mimics a Cellular 14-3-3-Binding Motif to Antagonize RIG-I- and MDA5-Mediated Innate Immunity. <i>Cell Host and Microbe</i> , 2019, 26, 493-503.e6.	5.1	91
141	Inactivation of Zika Virus by Photoactive Iodonaphthyl Azide Preserves Immunogenic Potential of the Virus. <i>Pathogens</i> , 2019, 8, 188.	1.2	3
142	Flavivirus infection—A review of immunopathogenesis, immunological response, and immunodiagnosis. <i>Virus Research</i> , 2019, 274, 197770.	1.1	61
143	Development of a Dengue Vaccine and Its Use in Pregnant Women. <i>Current Tropical Medicine Reports</i> , 2019, 6, 231-238.	1.6	1
144	Imported Zika virus infections in Hungary between 2016 and 2018. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2019, 66, 423-442.	0.4	1
145	Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors. <i>Viruses</i> , 2019, 11, 1019.	1.5	50

#	ARTICLE	IF	CITATIONS
146	Effects of Flavivirus Cross-Reactivity (Zika and Dengue) on the Development of Vaccines for Use in Pregnancy. <i>Current Tropical Medicine Reports</i> , 2019, 6, 223-230.	1.6	3
147	Development of a Potent and Protective Germline-Like Antibody Lineage Against Zika Virus in a Convalescent Human. <i>Frontiers in Immunology</i> , 2019, 10, 2424.	2.2	14
148	Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine. <i>Vaccines</i> , 2019, 7, 161.	2.1	16
149	A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy. <i>Cell Reports</i> , 2019, 28, 2634-2646.e4.	2.9	19
150	A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. <i>Nature Immunology</i> , 2019, 20, 1291-1298.	7.0	60
151	Zika virus proteins at an atomic scale: how does structural biology help us to understand and develop vaccines and drugs against Zika virus infection?. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2019, 25, e20190013.	0.8	21
152	Computationally Designed Peptides for Zika Virus Detection: An Incremental Construction Approach. <i>Biomolecules</i> , 2019, 9, 498.	1.8	9
153	High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007747.	1.3	20
154	A Chimeric Zika Virus between Viral Strains MR766 and BeH819015 Highlights a Role for E-glycan Loop in Antibody-mediated Virus Neutralization. <i>Vaccines</i> , 2019, 7, 55.	2.1	22
155	Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model. <i>Emerging Microbes and Infections</i> , 2019, 8, 749-759.	3.0	26
156	Characterization of two engineered dimeric Zika virus envelope proteins as immunogens for neutralizing antibody selection and vaccine design. <i>Journal of Biological Chemistry</i> , 2019, 294, 10638-10648.	1.6	8
157	Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy. <i>Journal of Virology</i> , 2019, 93, .	1.5	32
158	Expression and purification of domain III proteins from Dengue and Zika viruses. <i>Protein Expression and Purification</i> , 2019, 162, 38-43.	0.6	3
159	Comparative Analysis of African and Asian Lineage-Derived Zika Virus Strains Reveals Differences in Activation of and Sensitivity to Antiviral Innate Immunity. <i>Journal of Virology</i> , 2019, 93, .	1.5	51
160	Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein. <i>Journal of Virology</i> , 2019, 93, .	1.5	12
161	<i>Pichia pastoris</i> -expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation. <i>Pathogens and Disease</i> , 2019, 77, .	0.8	19
162	Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure. <i>Virologica Sinica</i> , 2019, 34, 168-174.	1.2	12
163	Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome. <i>Nature Communications</i> , 2019, 10, 1943.	5.8	44

#	ARTICLE	IF	CITATIONS
164	Structural Basis for Neutralization and Protection by a Zika Virus-Specific Human Antibody. <i>Cell Reports</i> , 2019, 26, 3360-3368.e5.	2.9	24
165	Rapid Synthetic DNA Vaccine Development for Emerging Infectious Disease Outbreaks. <i>Current Cancer Research</i> , 2019, , 347-362.	0.2	0
166	Exosomes mediate Zika virus transmission through SMPD3 neutral Sphingomyelinase in cortical neurons. <i>Emerging Microbes and Infections</i> , 2019, 8, 307-326.	3.0	94
167	A Vesicular Stomatitis Virus-Based Vaccine Carrying Zika Virus Capsid Protein Protects Mice from Viral Infection. <i>Virologica Sinica</i> , 2019, 34, 106-110.	1.2	8
168	Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus. <i>MBio</i> , 2019, 10, .	1.8	57
169	Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice. <i>Cell Reports</i> , 2019, 26, 1585-1597.e4.	2.9	18
170	Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise. <i>Frontiers in Microbiology</i> , 2019, 10, 29.	1.5	14
171	Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus. <i>Journal of Virology</i> , 2019, 93, .	1.5	19
172	Zika Vaccine Development: Current Status. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2572-2586.	1.4	69
173	A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virus. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	70
174	Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1591-1596.	3.3	53
175	Zika Virus Vaccine Development: Progress in the Face of New Challenges. <i>Annual Review of Medicine</i> , 2019, 70, 121-135.	5.0	76
176	Basics of memory B cell responses: lessons from and for the real world. <i>Immunology</i> , 2019, 156, 120-129.	2.0	24
177	Zika Vaccines. , 2019, , 75-88.		0
178	Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 907-918.	1.4	10
179	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. <i>Nature Communications</i> , 2020, 11, 5278.	5.8	30
180	Dengue and Zika virus multi-epitope antigen expression in insect cells. <i>Molecular Biology Reports</i> , 2020, 47, 7333-7340.	1.0	6
181	Affinity-Restricted Memory B Cells Dominate Recall Responses to Heterologous Flaviviruses. <i>Immunity</i> , 2020, 53, 1078-1094.e7.	6.6	76

#	ARTICLE	IF	CITATIONS
182	A complex between the Zika virion and the Fab of a broadly cross-reactive neutralizing monoclonal antibody revealed by cryo-EM and single particle analysis at 4.1Å... resolution. Journal of Structural Biology: X, 2020, 4, 100028.	0.7	3
183	Immunopathology of Zika virus infection. Advances in Virus Research, 2020, 107, 223-246.	0.9	0
184	Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement. EBioMedicine, 2020, 54, 102738.	2.7	11
185	Immune Reactivity of a 20-mer Peptide Representing the Zika E Glycan Loop Involves the Antigenic Determinants E-152/156/158. Viruses, 2020, 12, 1258.	1.5	2
186	Zika virus depletes neural stem cells and evades selective autophagy by suppressing the Fanconi anemia protein <scp>FANCC</scp>. EMBO Reports, 2020, 21, e49183.	2.0	17
187	Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics. Nature Biomedical Engineering, 2020, 4, 1030-1043.	11.6	46
188	Mapping the diverse structural landscape of the flavivirus antibody repertoire. Current Opinion in Virology, 2020, 45, 51-64.	2.6	22
189	Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking. Scientific Reports, 2020, 10, 18256.	1.6	9
190	Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge. Journal of Experimental Medicine, 2020, 217, .	4.2	26
191	Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli. Vaccines, 2020, 8, 492.	2.1	18
192	Structural Basis of Zika Virus Specific Neutralization in Subsequent Flavivirus Infections. Viruses, 2020, 12, 1346.	1.5	7
193	A Recombinant Zika Virus Envelope Protein with Mutations in the Conserved Fusion Loop Leads to Reduced Antibody Cross-Reactivity upon Vaccination. Vaccines, 2020, 8, 603.	2.1	10
194	Zika Virus. Methods in Molecular Biology, 2020, , .	0.4	0
195	Baculovirus Surface Display of Zika Virus Envelope Protein Protects against Virus Challenge in Mouse Model. Virologica Sinica, 2020, 35, 637-650.	1.2	13
196	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. Vaccines, 2020, 8, 307.	2.1	18
197	<i>In vivo</i> imaging of Zika virus reveals dynamics of viral invasion in immune-sheltered tissues and vertical propagation during pregnancy. Theranostics, 2020, 10, 6430-6447.	4.6	10
198	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine, 2020, 12, .	5.8	30
199	Probing the flexibility of Zika virus envelope protein DIII epitopes using molecular dynamics simulations. Molecular Simulation, 2020, 46, 541-547.	0.9	6

#	ARTICLE	IF	CITATIONS
200	Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity. <i>Vaccine</i> , 2020, 38, 3455-3463.	1.7	21
201	A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Journal of Immunology</i> , 2020, 205, 915-922.	0.4	186
202	The role of anti-flavivirus humoral immune response in protection and pathogenesis. <i>Reviews in Medical Virology</i> , 2020, 30, e2100.	3.9	25
203	A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein. <i>Cell Discovery</i> , 2020, 6, 5.	3.1	20
204	Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses. <i>Vaccine</i> , 2020, 38, 3653-3664.	1.7	17
205	Glycosylation as a tool for rational vaccine design. <i>Biotechnology and Bioengineering</i> , 2020, 117, 2556-2570.	1.7	15
206	Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9865-9875.	3.3	7
207	Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice. <i>Journal of Biomedical Science</i> , 2020, 27, 51.	2.6	6
208	Investigation of the immunogenicity of Zika glycan loop. <i>Virology Journal</i> , 2020, 17, 43.	1.4	9
209	Adjacent dimer epitope of envelope protein as an important region for Zika virus serum neutralization: a computational investigation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 1082-1092.	2.0	1
210	Hydrogen-deuterium exchange mass spectrometry identifies spatially distinct antibody epitopes on domain III of the Zika virus envelope protein. <i>Journal of Mass Spectrometry</i> , 2021, 56, e4685.	0.7	6
211	Zika Virus Is Transmitted in Neural Progenitor Cells via Cell-to-Cell Spread, and Infection Is Inhibited by the Autophagy Inducer Trehalose. <i>Journal of Virology</i> , 2021, 95, .	1.5	5
212	Graphene-based biosensors for the detection of Zika virus. , 2021, , 263-272.		0
213	A broadly protective antibody that targets the flavivirus NS1 protein. <i>Science</i> , 2021, 371, 190-194.	6.0	66
214	The use of monoclonal antibodies specific to flavivirus to develop therapeutic drugs. <i>Molekuliarnaia Genetika, Mikrobiologija i Virusologija</i> , 2021, 39, 3.	0.1	0
215	Plant-Produced Antigen Displaying Virus-Like Particles Evokes Potent Antibody Responses against West Nile Virus in Mice. <i>Vaccines</i> , 2021, 9, 60.	2.1	16
216	The development of human monoclonal antibodies against Zika virus. , 2021, , 359-366.		0
217	Landscape of Monoclonal Antibodies Targeting Zika and Dengue: Therapeutic Solutions and Critical Insights for Vaccine Development. <i>Frontiers in Immunology</i> , 2020, 11, 621043.	2.2	16

#	ARTICLE	IF	CITATIONS
218	Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients. <i>Frontiers in Immunology</i> , 2021, 12, 615102.	2.2	15
219	Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009195.	1.3	14
220	Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody. <i>Biochemical and Biophysical Research Communications</i> , 2021, 545, 33-39.	1.0	6
221	Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine. <i>Virology Journal</i> , 2021, 18, 50.	1.4	1
222	Interactions between timing and transmissibility explain diverse flavivirus dynamics in Fiji. <i>Nature Communications</i> , 2021, 12, 1671.	5.8	3
223	Refocusing the Immune Response to Selected Epitopes on a Zika Virus Protein Antigen by Nanopatterning. <i>Advanced Healthcare Materials</i> , 2021, 10, 2002140.	3.9	6
224	Structural and biochemical insights into flavivirus proteins. <i>Virus Research</i> , 2021, 296, 198343.	1.1	6
225	Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	22
226	Using Flavivirus-Specific Monoclonal Antibodies to Study the Antigenic Structure of Flaviviruses and Develop Anti-Flavivirus Drugs. <i>Molecular Genetics, Microbiology and Virology</i> , 2021, 36, 57-67.	0.0	0
227	Development and characterization of mouse monoclonal antibodies targeting to distinct epitopes of Zika virus envelope protein for specific detection of Zika virus. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 4663-4673.	1.7	8
228	A Virus-Like Particle-Based Vaccine Candidate against the Tick-Borne Powassan Virus Induces Neutralizing Antibodies in a Mouse Model. <i>Pathogens</i> , 2021, 10, 680.	1.2	6
229	<scp>RosettaCM</scp> for antibodies with very long <scp>HCDR3s</scp> and low template availability. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 1458-1472.	1.5	3
230	The key amino acids of E protein involved in early flavivirus infection: viral entry. <i>Virology Journal</i> , 2021, 18, 136.	1.4	26
231	Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch. <i>Nature Immunology</i> , 2021, 22, 958-968.	7.0	23
232	Mechanism through Which Retrocyclin Targets Flavivirus Multiplication. <i>Journal of Virology</i> , 2021, 95, e0056021.	1.5	6
233	Current development of Zika virus vaccines with special emphasis on virus-like particle technology. <i>Expert Review of Vaccines</i> , 2021, 20, 1483-1498.	2.0	8
234	The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking <i>De Novo</i> Formation of the Membranous Replication Compartment. <i>Journal of Virology</i> , 2021, 95, e0099621.	1.5	11
235	Are the Organoid Models an Invaluable Contribution to ZIKA Virus Research?. <i>Pathogens</i> , 2021, 10, 1233.	1.2	6

#	ARTICLE	IF	CITATIONS
236	Evaluating Zika Virus Pathogenesis in Immunocompromised Mice. <i>Methods in Molecular Biology</i> , 2020, 2142, 23-40.	0.4	1
237	Development and Expression of Subunit Vaccines Against Viruses in Plants. <i>Methods in Molecular Biology</i> , 2021, 2225, 25-38.	0.4	5
238	Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	93
239	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. <i>Nature Medicine</i> , 2020, 26, 228-235.	15.2	61
240	Molecular Basis of Differential Stability and Temperature Sensitivity of ZIKA versus Dengue Virus Protein Shells. <i>Scientific Reports</i> , 2020, 10, 8411.	1.6	8
241	In vitro and in vivo models for studying Zika virus biology. <i>Journal of General Virology</i> , 2018, 99, 1529-1550.	1.3	40
242	Delineating antibody recognition against Zika virus during natural infection. <i>JCI Insight</i> , 2017, 2, .	2.3	61
243	Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development. <i>F1000Research</i> , 2018, 7, 1624.	0.8	4
244	Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species. <i>PLOS Currents</i> , 2016, 8, .	1.4	64
245	Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005296.	1.3	103
246	Zika virus-like particle (VLP) based vaccine. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005608.	1.3	126
247	Zika virus like particles elicit protective antibodies in mice. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006210.	1.3	28
248	Preconceptual Zika virus asymptomatic infection protects against secondary prenatal infection. <i>PLoS Pathogens</i> , 2017, 13, e1006684.	2.1	22
249	Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2020, 26, e20200019.	0.8	9
250	ANALYSIS OF DOMAIN SPECIFICITY OF THE PROTECTIVE CHIMERIC ANTIBODY ch14D5a AGAINST GLYCOPROTEIN E OF TICK-BORNE ENCEPHALITIS VIRUS. <i>Vavilovskii Zhurnal Genetiki i Seleksii</i> , 2018, 22, 459-467.	0.4	6
251	Advances in Designing and Developing Vaccines Against Zika Virus. <i>International Journal of Pharmacology</i> , 2017, 13, 667-676.	0.1	2
252	How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. <i>Viruses</i> , 2021, 13, 2106.	1.5	7
254	Development of a neutralizing antibody targeting linear epitope of the envelope protein III of ZIKV. <i>Virus Research</i> , 2021, 306, 198601.	1.1	1

#	ARTICLE	IF	CITATIONS
256	INFLUÊNCIA DE DIFERENTES MEIOS DE CULTURA NA PRODUÇÃO SOLÚVEL DO DOMÍNIO III DA PROTEÍNA DE ENVELOPE DO VÍRUS ZIKA EM ESCHERICHIA COLI. , 0, , .		0
259	Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development. <i>F1000Research</i> , 2018, 7, 1624.	0.8	4
263	Isolation of Monoclonal Antibodies from Zika Virus-Infected Patient Samples. <i>Methods in Molecular Biology</i> , 2020, 2142, 261-288.	0.4	1
265	Identification of Potential Lead Molecules for Zika Envelope Protein from In Silico Perspective. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 94-103.	0.2	1
267	Multiplexed, High-Sensitivity Measurements of Antibody Affinity Using Interferometric Reflectance Imaging Sensor. <i>Biosensors</i> , 2021, 11, 483.	2.3	5
268	Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo. <i>Cell Chemical Biology</i> , 2022, 29, 811-823.e7.	2.5	6
269	Replication is the key barrier during the dual-host adaptation of mosquito-borne flaviviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2110491119.	3.3	7
270	ZIKV B-cell epitopes for immunodiagnostic tests. <i>Journal of Immunological Methods</i> , 2022, 504, 113246.	0.6	0
271	Zika Virus Overview: Transmission, Origin, Pathogenesis, Animal Model and Diagnosis. <i>Zoonoses</i> , 2021, 1, .	0.5	10
272	Structural basis of malaria transmission blockade by a monoclonal antibody to gamete fusogen HAP2. <i>ELife</i> , 2021, 10, .	2.8	7
274	Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract. <i>Npj Vaccines</i> , 2022, 7, 43.	2.9	12
275	Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins. <i>Antiviral Research</i> , 2022, 202, 105325.	1.9	9
281	Intranasal Immunization with Zika Virus Envelope Domain III-Flagellin Fusion Protein Elicits Systemic and Mucosal Immune Responses and Protection against Subcutaneous and Intravaginal Virus Challenges. <i>Pharmaceutics</i> , 2022, 14, 1014.	2.0	6
282	Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function. <i>Journal of Virology</i> , 2022, , e0007122.	1.5	2
283	It is Never Too Late for a Cocktail - Development and Analytical Characterization of Fixed-dose Antibody Combinations. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2149-2157.	1.6	2
284	Pathogenesis and Manifestations of Zika Virus-Associated Ocular Diseases. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 106.	0.9	8
285	A Powassan virus domain III nanoparticle immunogen elicits neutralizing and protective antibodies in mice. <i>PLoS Pathogens</i> , 2022, 18, e1010573.	2.1	6
286	A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity. <i>BMC Biology</i> , 2022, 20, .	1.7	3



#	ARTICLE	IF	CITATIONS
287	In Vitro Neutralisation of Zika Virus by an Engineered Protein Targeting the Viral Envelope Fusion Loop. SSRN Electronic Journal, 0, , .	0.4	1
288	Reporter Flaviviruses as Tools to Demonstrate Homologous and Heterologous Superinfection Exclusion. <i>Viruses</i> , 2022, 14, 1501.	1.5	7
289	Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010588.	1.3	2
290	Serological cross-reactivity among common flaviviruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	27
291	ZIKV-envelope proteins induce specific humoral and cellular immunity in distinct mice strains. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
292	Current Advances in Zika Vaccine Development. <i>Vaccines</i> , 2022, 10, 1816.	2.1	27
295	A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization. <i>Cell</i> , 2022, 185, 4826-4840.e17.	13.5	11
296	In vitro neutralisation of Zika virus by an engineered protein targeting the viral envelope fusion loop. <i>Molecular Systems Design and Engineering</i> , 0, , .	1.7	0
297	Using deep-learning predictions of inter-residue distances for model validation. <i>Acta Crystallographica Section D: Structural Biology</i> , 2022, 78, 1412-1427.	1.1	6
298	Vaccination with a Zika virus envelope domain III protein induces neutralizing antibodies and partial protection against Asian genotype in immunocompetent mice. <i>Tropical Medicine and Health</i> , 2022, 50, .	1.0	2
299	Influence of Dosing Regimen and Adjuvant Type on the Immunogenicity of Novel Recombinant Zika Virus-Like Particles. <i>Microbiology Spectrum</i> , 0, , .	1.2	0
300	prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	4
301	Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus. <i>Vaccines</i> , 2023, 11, 197.	2.1	5
302	A method for mapping the linear epitopes targeted by the natural antibody response to Zika virus infection using a VLP platform technology. <i>Virology</i> , 2023, 579, 101-110.	1.1	3
304	Zika virus spreads through infection of lymph node-resident macrophages. <i>Cell Reports</i> , 2023, 42, 112126.	2.9	11
305	Comparative mutational analysis of the Zika virus genome from different geographical locations and its effect on the efficacy of Zika virus-specific neutralizing antibodies. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	2
306	B-cell epitope discovery: The first protein flexibility-based algorithmâ€™s Zika virus conserved epitope demonstration. <i>PLoS ONE</i> , 2023, 18, e0262321.	1.1	1
307	Diagnostic and vaccine potential of Zika virus envelope protein (E) derivatives produced in bacterial and insect cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1

#	ARTICLE	IF	CITATIONS
308	Plant-Produced Anti-Zika Virus Monoclonal Antibody Glycovariant Exhibits Abrogated Antibody-Dependent Enhancement of Infection. <i>Vaccines</i> , 2023, 11, 755.	2.1	4
309	A Ferritin Nanoparticle-Based Zika Virus Vaccine Candidate Induces Robust Humoral and Cellular Immune Responses and Protects Mice from Lethal Virus Challenge. <i>Vaccines</i> , 2023, 11, 821.	2.1	4
311	An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection. <i>Npj Vaccines</i> , 2023, 8, .	2.9	7
317	Zika Virus <i>Vaccines</i> . , 2023, , 1322-1333.e7.		0